Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr;36(4):e49.
doi: 10.2337/dc12-1987.

Pancreatitis associated with incretin-based therapies

Shridhar N Iyer, Robert J Tanenberg, Carlos E Mendez, R Lee West, Almond J Drake 3rd

Pancreatitis associated with incretin-based therapies

Shridhar N Iyer et al. Diabetes Care. 2013 Apr.
No abstract available

PubMed Disclaimer

References

    1. Patel MB, Elmore LK, Edgerton LP, Whalin LM. Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus. Am J Health Syst Pharm 2012;69:1044–1048 - PubMed
    1. Violante R, Oliveira JHA, Yoon KH, et al. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin. Diabet Med 2012;29:e417–e424 - PubMed
    1. U.S. Food and Drug Administration Drugs: Information for healthcare professionals: exenatide (marketed as Byetta) [Internet], 2008. Available from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPa... Accessed 16 September 2012
    1. U.S. Food and Drug Administration Safety: Sitagliptin (marketed as Januvia and Janumet) –acute pancreatitis [Internet], 2009. Available from http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHuma... Accessed 16 September 16 2012
    1. Iyer SN, Drake AJ, West RL, et al. Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide. Endocr Pract 2012;18:e10–e13 - PubMed